Lovastatin Inhibits RhoA to Suppress Canonical Wnt/β-Catenin Signaling and Alternative Wnt-YAP/TAZ Signaling in Colon Cancer.

Authors

Yi Xiao
Qin Liu
Nanyin Peng
Yuzhang Li
Danyang Qiu
Tianlun Yang
Richard Kang
Ahsan Usmani, Lehigh Valley Health NetworkFollow
Efosa Amadasu
Cesario V Borlongan
Guolong Yu

Publication/Presentation Date

1-1-2022

Abstract

Statins are first-line drugs used to control patient lipid levels, but there is recent evidence that statin treatment can lower colorectal cancer (CRC) incidence by 50% and prolong CRC patient survival through mechanisms that are poorly understood. In this study, we found that the treatment of APC

Volume

31

First Page

9636897221075749

Last Page

9636897221075749

ISSN

1555-3892

Published In/Presented At

Xiao, Y., Liu, Q., Peng, N., Li, Y., Qiu, D., Yang, T., Kang, R., Usmani, A., Amadasu, E., Borlongan, C. V., & Yu, G. (2022). Lovastatin Inhibits RhoA to Suppress Canonical Wnt/β-Catenin Signaling and Alternative Wnt-YAP/TAZ Signaling in Colon Cancer. Cell transplantation, 31, 9636897221075749. https://doi.org/10.1177/09636897221075749

Disciplines

Medical Education | Medicine and Health Sciences

PubMedID

35168393

Department(s)

USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type

Article